Skip to content

Source filing unavailable

Q4 2015 · —
Revenue$340.88M+3.9% vs Q4 2014+0.0% vs Q3 2015
Net Income$82.76M+1.4% vs Q4 2014−5.9% vs Q3 2015
EPS Diluted$1.32+1.5% vs Q4 2014−5.0% vs Q3 2015
Gross Profit$314,894,000+6.6%
Operating Incomederived$106,628,000−17.9%
Operating Cash Flowderived$119,741,000−10.8%
Free Cash Flowderived$116,374,000−3.6%
Margins · derived
Gross margin92.4%+2.3 pt vs Q4 2014
Operating margin31.3%−8.3 pt vs Q4 2014
Net margin24.3%−0.6 pt vs Q4 2014

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-Q.

Same quarter

MetricQ4 2015Q4 2014Q4 2013Q4 2012
Revenue$340.88M$328.14M$235.77M$183.70M
Net Income$82.76M$81.61M$55.29M$200.55M
EPS Diluted$1.32$1.30$0.90$3.28

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Jazz Pharmaceuticals plc · CIK 1232524 · Engraved from SEC EDGAR